Efficacy of sunitinib and radiotherapy in genetically engineered mouse model of soft-tissue sarcoma.

ABSTRACT:

Purpose

Sunitinib (SU) is a multitargeted receptor tyrosine kinase inhibitor of the vascular endothelial growth factor and platelet-derived growth factor receptors. The present study examined SU and radiotherapy (RT) in a genetically engineered mouse model of soft tissue sarcoma (STS).

Methods and materials

Primary extremity STSs were generated in genetically engineered mice. The mice were randomized to treatment with SU, RT (10 Gy x 2), or both (SU+RT). Changes in the tumor vasculature before and after treatment were assessed in vivo using fluorescence-mediated tomography. The control and treated tumors were harvested and extensively analyzed.

Results

The mean fluorescence in the tumors was not decreased by RT but decreased 38-44% in tumors treated with SU or SU+RT.

SUBMITTER: Yoon SS 

PROVIDER: S-EPMC2733223 | biostudies-literature | 2009 Jul

REPOSITORIES: biostudies-literature